Ignasi Barber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ignasi Barber has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Soldado
Pediatric Hand Surgery and Microsurgery, Barcelona Children's Hospital, HM Nens, HM Hospitales Barcelona Spain
12 shared publications - Anabel Martínez-Romero
Josep Carreras Leukaemia Research Institute 3 Barcelona
10 shared publications - Andrew K. Ressler
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, USA
10 shared publications - Asunción Vicente
Department of Dermatology, Hospital Sant Joan de Déu, Barcelona, Spain
10 shared publications - Carlota Rovira
Department of Pathology, Hospital Sant Joan de Déu, Barcelona, Spain
10 shared publications - Douglas A. Marchuk
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, USA
10 shared publications
Latest Publications
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Loss of endothelial PTEN protein expression in vascular malformations of patients with PHTS.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Loss of endothelial PTEN protein expression in vascular malformations of patients with PHTS.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
PTEN loss in ECs causes lymphatic vascular malformations in the ear skin of mice.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
PTEN loss in ECs causes lymphatic vascular malformations in the ear skin of mice.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Preclinical study of alpelisib in mice with PTEN-related vascular malformations.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Preclinical study of alpelisib in mice with PTEN-related vascular malformations.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Clinical characteristics of vascular malformations in patients with PHTS; related to Figure 1.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Clinical characteristics of vascular malformations in patients with PHTS; related to Figure 1.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Patients with PHTS treated with rapamycin; related to Figure 4.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Patients with PHTS treated with rapamycin; related to Figure 4.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Somatic allelic imbalance analysis using MoChA.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Somatic allelic imbalance analysis using MoChA.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
PTEN loss in ECs causes blood vascular malformations in mice.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
PTEN loss in ECs causes blood vascular malformations in mice.
- 28 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (7) , 1350-1362
Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
PTEN hamartoma tumor syndrome (PHTS) is a rare tumor risk disorder caused by germline loss-of-function mutations in PTEN. Half of these patients develop vascular malformations, a hamartoma characterized by overgrowth of vessels. In this study, we harness biopsies and patient-derived endothelial cells (EC) to study the genetic etiology of PHTS-related vascular malformations. We discover that these lesions are generated by somatic loss of the PTEN wild-type allele through copy-neutral loss of heterozygosity, leading to somatic uniparental disomy of the PTEN-mutated allele in ECs. We established a mouse model of PHTS-related vascular malformations and identified that the mTOR inhibitor rapamycin and AKT inhibitor capivasertib block vascular lesion growth. As proof-of-concept for clinical activity, off-label treatment with rapamycin of two patients with PHTS reduced vascular overgrowth and abrogated lesion-associated pain. Overall, our results uncover the genetic cause of vascular malformations in patients with PHTS and open new avenues for therapeutic intervention. Significance: Somatic loss of PTEN in ECs causes vascular malformations in patients with the tumor risk syndrome PHTS. These lesions respond to PI3K signaling inhibition. See related commentary by Del Prior and Toker, p. 1306
- 28 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (7) , 1350-1362
Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
PTEN hamartoma tumor syndrome (PHTS) is a rare tumor risk disorder caused by germline loss-of-function mutations in PTEN. Half of these patients develop vascular malformations, a hamartoma characterized by overgrowth of vessels. In this study, we harness biopsies and patient-derived endothelial cells (EC) to study the genetic etiology of PHTS-related vascular malformations. We discover that these lesions are generated by somatic loss of the PTEN wild-type allele through copy-neutral loss of heterozygosity, leading to somatic uniparental disomy of the PTEN-mutated allele in ECs. We established a mouse model of PHTS-related vascular malformations and identified that the mTOR inhibitor rapamycin and AKT inhibitor capivasertib block vascular lesion growth. As proof-of-concept for clinical activity, off-label treatment with rapamycin of two patients with PHTS reduced vascular overgrowth and abrogated lesion-associated pain. Overall, our results uncover the genetic cause of vascular malformations in patients with PHTS and open new avenues for therapeutic intervention. Significance: Somatic loss of PTEN in ECs causes vascular malformations in patients with the tumor risk syndrome PHTS. These lesions respond to PI3K signaling inhibition. See related commentary by Del Prior and Toker, p. 1306